Cystic Fibrosis Lung Disease Modifiers and Their Relevance in the New Era of Precision Medicine.

Our understanding of cystic fibrosis (CF) has grown exponentially since the discovery of the cystic fibrosis transmembrane conductance regulator () gene in 1989. With evolving genetic and genomic tools, we have come to better understand the role of genotypes in the pathophysiology of the disease. This, in turn, has paved the way for the development of modulator therapies targeted at mutations in the , which are arguably one of the greatest advances in the treatment of CF.

Improving the transport of urgent specimens to an off-site laboratory using a novel sticker-tracker.

Obtaining results for urgent microbiology specimens in an efficient manner is imperative to ensure that patients receive appropriate antibiotic therapy. A previous audit carried out in the Paediatric department of a central teaching hospital and a number of clinical incidents, highlighted a delay in transport of specimens (exceeding eight hours) and 'missing' specimens. This results in empirical antibiotic treatment of infection, with delay in confirming microbiology result and unnecessary, distressing repeat investigation.